Corixa Announces Sale and Transfer Of BEXXAR Development and Marketing Rights To GlaxoSmithKline.
Business Wire › December 13, 2004
Linked as:
Extract
Corixa Announces Sale and Transfer Of BEXXAR Development and Marketing Rights To GlaxoSmithKline.
SEATTLE -- Corixa to Focus on Adjuvant Commercialization and TLR4 Agonist/Antagonist Product Development; Restructuring Expected to Result in More Than 50 Percent Reduction in Cash Burn
Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced that it has reached an agreement with GlaxoSmithKline (GSK) pursuant to which GSK will acquire worldwide rights and re...See the full content of this document
Sponsored links
